Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Antibe Therapeutics Inc (ATBPF)

Antibe Therapeutics Inc (ATBPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Antibe’s Chief Medical Officer to Present at the 2023 Precision in Clinical Trials Summit Business Wire - Tue Apr 25, 2023

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference Business Wire - Tue Apr 18, 2023

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, today announced its...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Provides April 2023 Corporate Update Business Wire - Tue Apr 11, 2023

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to provide...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Reports Q3 2023 Interim Financial and Operating Results Business Wire - Wed Feb 15, 2023

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Reports Q2 2023 Interim Financial and Operating Results Business Wire - Tue Nov 15, 2022

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, has filed its financial...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Closes Previously Announced Strategic Sale of Citagenix Subsidiary Business Wire - Wed Nov 2, 2022

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies to target inflammation, is pleased to announce...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Provides Development Update for Otenaproxesul Business Wire - Wed Oct 12, 2022

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Announces Results of 2022 Annual Meeting Business Wire - Fri Sep 9, 2022

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Academic Collaborator to Present Clinical Data at PAINWeek 2022 Business Wire - Tue Sep 6, 2022

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, is pleased to announce...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)
Antibe Therapeutics Reports Q1 2023 Interim Financial and Operating Results Business Wire - Mon Aug 15, 2022

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies that target inflammation, has filed its financial...

ATE.TO : 0.2950 (+13.46%)
ATBPF : 0.2156 (+13.47%)

Barchart Exclusives

After Its Historic Dividend Cut, Is 3M Stock Still Worth Buying? Barchart - 1 hour ago
3M stock is a Dividend King no more, as the company slashed its payout following the Solventum spinoff. Is the stock still a buy for investors seeking passive income? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot